Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FENTORA vs ALFENTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a potent mu-opioid receptor agonist, binding to and activating opioid receptors in the brain and spinal cord, leading to analgesia and sedation.
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
Management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
For opioid-tolerant adults: 100 mcg (one tablet) placed in buccal cavity; titrate upward in increments of 100 mcg per breakthrough pain episode, with minimum 2-hour interval between doses; maximum 4 doses per day.
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
Terminal elimination half-life is approximately 2–4 hours in adults, but can range from 2 to 6 hours depending on hepatic clearance. In elderly or hepatically impaired patients, half-life may be prolonged. The rapid initial decline is due to redistribution, and the terminal phase reflects slow elimination from deep compartments.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
FENTORA is primarily metabolized by CYP3A4 to norfentanyl and other metabolites.
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
Primarily renal: Approximately 75% of the dose is excreted in urine as metabolites (mostly norfentanyl, despropionylfentanyl, and hydroxyfentanyl), with less than 7% as unchanged fentanyl. Fecal elimination accounts for about 9%.
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
Approximately 80–85% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein (AAG). Binding is concentration-dependent and may decrease in conditions with low albumin or elevated AAG.
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
Volume of distribution (Vd) is 3–6 L/kg, indicating extensive tissue distribution. Large Vd reflects high lipophilicity and rapid uptake into tissues such as fat and muscle, contributing to redistribution and prolonged effects with repeated doses.
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
Buccal administration: Absolute bioavailability is approximately 65–70% due to first-pass metabolism and some swallowed drug. Sublingual delivery is similar, but variability is high. Compared to IV, buccal bioavailability is consistent at ~65%.
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
For GFR <30 m L/min: initiate at 50 mcg (half a 100 mcg tablet) and titrate cautiously; no specific adjustment for GFR 30-89 m L/min.
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
Child-Pugh Class A or B: initiate at 50 mcg and titrate cautiously; Child-Pugh Class C: not recommended.
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
Not approved for use in pediatric patients (safety and efficacy not established).
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
Initiate at 50 mcg in patients aged ≥65 years and titrate cautiously; monitor for respiratory depression and cognitive impairment.
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
WARNING: RISK OF MEDICATION ERRORS; ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; NEONATAL OPIOID WITHDRAWAL SYNDROME; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; RISK OF SEROTONIN SYNDROME; RISK OF ADRENAL INSUFFICIENCY; SEVERE HYPOTENSION; GASTROINTESTINAL ADVERSE REACTIONS; SEIZURES; AND INCREASED INTRACRANIAL PRESSURE, HEAD INJURY, OR IMPAIRED CONSCIOUSNESS.
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Life-threatening respiratory depression,Addiction, abuse, and misuse,Risk of medication errors (dosing and product confusion),Accidental exposure (especially in children),Neonatal opioid withdrawal syndrome,Risks from concomitant use with benzodiazepines or other CNS depressants,Interaction with alcohol,Risk of serotonin syndrome,Risk of adrenal insufficiency,Severe hypotension,Gastrointestinal adverse reactions (e.g., constipation),Seizures,Increased intracranial pressure,Use in patients with head injury or impaired consciousness
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
Opioid non-tolerant patients,Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Known hypersensitivity to fentanyl or any components of FENTORA
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
Avoid grapefruit juice and grapefruit products as they inhibit CYP3A4 and can increase fentanyl levels, raising risk of respiratory depression and QT prolongation. Do not consume alcohol; additive CNS depression may occur. No other known significant food interactions; however, avoid high-fat meals immediately before or after administration as they may alter absorption.
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
Insufficient human data; animal studies show increased skeletal anomalies and reduced fetal weight at high doses. Fentanyl is not a major teratogen but chronic use may cause neonatal opioid withdrawal syndrome (NOWS) in third trimester. Avoid in pregnancy unless benefits outweigh risks.
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
Fentanyl is excreted in breast milk; M/P ratio not established but assumed similar to parenteral fentanyl (M/P ~0.5-1). Effect on infant minimal with single use, but chronic use may lead to opioid exposure. Use caution and monitor infant for sedation and respiratory depression.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
No specific dose adjustments for fentanyl in pregnancy; pharmacokinetic changes may require higher doses due to increased clearance and volume of distribution. Use lowest effective dose and titrate to effect.
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
FENTORA (fentanyl buccal tablet) is an immediate-release opioid indicated only for breakthrough pain in opioid-tolerant cancer patients. Do not use in opioid-naive patients due to risk of fatal respiratory depression. The tablet must not be split, crushed, or chewed; place in buccal cavity. Onset of analgesia occurs within 15 minutes. Due to QT prolongation risk, avoid use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) and in patients with electrolyte abnormalities. Follow single-tablet administration and wait at least 2 hours before treating another episode. Tear the blister pack before placing; do not store opened blister.
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
Use only for breakthrough pain if you are already taking around-the-clock opioid medication and are tolerant to it.,Do not use this medicine if you have not taken opioids before; it can cause life-threatening breathing problems.,Place the entire tablet in your cheek pouch above a back molar; do not crush, chew, or swallow it.,Allow tablet to dissolve completely; do not eat or drink until it has fully dissolved (about 14–25 minutes).,If you get more than one breakthrough pain episode per day, contact your doctor; do not increase the dose on your own.,Store in original sealed blister pack; keep out of reach of children and dispose of unused tablets properly.,Avoid alcohol and grapefruit juice while using this medicine.,Do not drive or operate machinery until you know how this medicine affects you.
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
No interactions on record
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FENTORA vs ALFENTA, answered by our medical review team.
FENTORA is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, binding to and activating opioid receptors in the brain and spinal cord, leading to analgesia and sedation.. ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FENTORA and ALFENTA depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FENTORA is: For opioid-tolerant adults: 100 mcg (one tablet) placed in buccal cavity; titrate upward in increments of 100 mcg per breakthrough pain episode, with minimum 2-hour interval between doses; maximum 4 doses per day.. The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FENTORA and ALFENTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FENTORA is classified as Category C. Insufficient human data; animal studies show increased skeletal anomalies and reduced fetal weight at high doses. Fentanyl is not a major teratogen but chronic use may cause neonat. ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.